Health Care & Life Sciences » Biotechnology | Emergent Biosolutions Inc.

Emergent Biosolutions Inc. | Balance Sheet

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
179
280
308
272
179
112
Total Accounts Receivable
66
60
120
148
146
272
Inventories
15
66
61
74
143
206
Other Current Assets
13
26
48
16
17
30
Total Current Assets
273
432
537
510
485
621
Net Property, Plant & Equipment
264
314
328
376
407
510
Intangible Assets
86
178
82
75
169
1,071
Other Assets
3
8
79
2
6
14
Total Assets
627
945
1,037
970
1,070
2,229
ST Debt & Current Portion LT Debt
-
-
-
20
-
Accounts Payable
28
41
38
35
42
Income Tax Payable
-
-
-
-
-
Other Current Liabilities
29
52
62
51
58
Total Current Liabilities
57
93
100
106
100
Long-Term Debt
62
251
247
248
13
Provision for Risks & Charges
15
41
23
10
10
Deferred Taxes
-
13
11
6
3
Other Liabilities
4
7
8
10
34
Total Liabilities
137
392
377
374
158
Common Equity (Total)
490
553
660
596
912
Total Shareholders' Equity
490
553
660
596
912
Total Equity
489
553
660
596
912
Liabilities & Shareholders' Equity
627
945
1,037
970
1,070
Accumulated Minority Interest
-
-
-
-
-

About Emergent Biosolutions

View Profile
Address
400 Professional Drive
Gaithersburg Maryland 20879
United States
Employees -
Website http://www.emergentbiosolutions.com
Updated 07/08/2019
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures that address public health and national security threats. It includes Chemical, Biological, Radiological, Nuclear and Explosive or CBRNE threats; as well as emerging infectious diseases. Its business units include Vaccines and Anti-Infectives; Antibody Therapeutics; Devices; and Contract Development and Manufacturing.